Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (951-960 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|May 29, 2015
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-lifeColby A Souders, Stuart C Nelson, Yang Wang, et al.
Mabs|May 24, 2021
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodiesRomain Rouet, Ohan Mazigi, Gregory J Walker, et al.
Mabs|May 25, 2021
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion proteinTakuo Suzuki, Noritaka Hashii, Minoru Tada, et al.
Mabs|May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapyInja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
Mabs|August 4, 2021
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodiesMaxwell A Stefan, Yooli K Light, Jennifer L Schwedler, et al.
Mabs|February 14, 2023
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-lifeEmma Davé, Oliver Durrant, Neha Dhami, et al.
Mabs|November 12, 2016
The TGF-β inhibitory activity of antibody 37E1B5 depends on its H-CDR2 glycanPing Tsui, Daniel R Higazi, Yanli Wu, et al.
Mabs|December 9, 2016
Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degenerationKun Ding, Lucia Eaton, Diana Bowley, et al.
Mabs|October 30, 2016
Corrigendum
Mabs|March 22, 2017
Transmembrane TNF-dependent uptake of anti-TNF antibodiesArun Deora, Subramanya Hegde, Jacqueline Lee, et al.
Pageof 184

Showing results (951-960 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|May 29, 2015
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-lifeColby A Souders, Stuart C Nelson, Yang Wang, et al.
Mabs|May 24, 2021
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodiesRomain Rouet, Ohan Mazigi, Gregory J Walker, et al.
Mabs|May 25, 2021
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion proteinTakuo Suzuki, Noritaka Hashii, Minoru Tada, et al.
Mabs|May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapyInja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
Mabs|August 4, 2021
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodiesMaxwell A Stefan, Yooli K Light, Jennifer L Schwedler, et al.
Mabs|February 14, 2023
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-lifeEmma Davé, Oliver Durrant, Neha Dhami, et al.
Mabs|November 12, 2016
The TGF-β inhibitory activity of antibody 37E1B5 depends on its H-CDR2 glycanPing Tsui, Daniel R Higazi, Yanli Wu, et al.
Mabs|December 9, 2016
Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degenerationKun Ding, Lucia Eaton, Diana Bowley, et al.
Mabs|October 30, 2016
Corrigendum
Mabs|March 22, 2017
Transmembrane TNF-dependent uptake of anti-TNF antibodiesArun Deora, Subramanya Hegde, Jacqueline Lee, et al.
Pageof 184